Ignyta, Inc. (Nasdaq: RXDX) announced data examining the combination of entrectinib and trametinib in overcoming resistance to TRK inhibition during ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE